Sodium-glucose cotransporter 2 (SGLT2) inhibitors can also improve steatosis and reduce hepatic triglyceride content in patients with MAFLD and have demonstrated cardiovascular benefits in patients with heart failure and type 2 diabetes [179,180]. Here, SLC5A2 is linked to heart failure.